Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

NIH

Sponsor class

Conditions

Metastatic Esophageal Carcinoma
Metastatic Gastric Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Recurrent Esophageal Carcinoma
Recurrent Gastric Carcinoma
Recurrent Gastroesophageal Junction Adenocarcinoma
Stage III Esophageal Cancer AJCC v7
Stage III Gastric Cancer AJCC v7
Stage IV Esophageal Cancer AJCC v7
Stage IV Gastric Cancer AJCC v7
Unresectable Esophageal Carcinoma
Unresectable Gastric Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Olaparib
BIOLOGICAL: Ramucirumab

Sponsor

National Cancer Institute (NCI)